What Promedius does
Promedius develops AI-powered diagnostic software including PROS CXR: OSTEO, which analyzes chest X-ray images to screen patients for osteoporosis risk, and abdominal CT-based muscle and fat segmentation tools. The company received FDA manufacturing approval for its software in March 2025 and signed a sales and distribution agreement for OsteoSignal with Daewoong Pharmaceutical in August 2026. Promedius was founded in Seoul in 2019 as a spin-off from Asan Medical Center's Medical Imaging and Intelligent Reality Lab.
Promedius is a healthcare tool on Falcoscan. AI software that screens chest X-rays for osteoporosis risk. Falcoscan rates Promedius with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Promedius is founded in 2019, currently at Series_b stage. Pricing: Paid.